Table 1 Socio-demographic and clinical characteristics of the SATS participants (n = 1017)
Variable | EOAD (n = 143 [14%]) | LOAD (n = 874 [86%]) | p Value |
|---|---|---|---|
n/% | n/% | ||
Female sex | 82/57% | 568/65% | 0.091 |
APOE genotype (n = 996) | < 0.001 | ||
No ε4 alleles | 36/25% | 284/33% | |
One ε4 allele | 66/46% | 459/54% | |
Two ε4 alleles | 41/29% | 110/13% | |
Solitary living at baseline | 30/21% | 322/37% | < 0.001 |
Completion rate after 3 years | 57/40% | 318/36% | 0.425 |
Antihypertensives/cardiac therapy | 28/20% | 384/44% | < 0.001 |
Antidiabetics | 5/3% | 45/5% | 0.397 |
Asthma medication | 9/6% | 34/4% | 0.185 |
Thyroid therapy | 9/6% | 76/9% | 0.336 |
Lipid-lowering agents | 16/11% | 101/12% | 0.898 |
Oestrogens | 9/6% | 60/7% | 0.801 |
NSAIDs/acetylsalicylic acid | 15/10% | 288/33% | < 0.001 |
Antidepressants | 41/29% | 215/25% | 0.298 |
Antipsychotics | 2/1% | 43/5% | 0.058 |
Anxiolytics/sedatives/hypnotics | 6/4% | 141/16% | < 0.001 |
Variable | Mean ± SD | Mean ± SD | p Value |
Estimated age at onset, years, range | 58.6 ± 4.7, 45–64 | 74.4 ± 4.9, 65–88 | < 0.001 |
Estimated duration of AD at baseline, years | 4.1 ± 3.4 | 2.9 ± 1.7 | < 0.001 |
Age at first assessment, years | 62.7 ± 5.4 | 77.3 ± 4.7 | < 0.001 |
Education, years | 10.1 ± 2.8 | 9.3 ± 2.5 | 0.004 |
MMSE score at baseline | 21.4 ± 3.8 | 21.4 ± 3.7 | 0.987 |
ADAS-Cog score (0–70) at baseline | 19.5 ± 9.6 | 21.0 ± 8.8 | 0.074 |
IADL score at baseline | 13.9 ± 5.3 | 16.3 ± 5.4 | < 0.001 |
PSMS score at baseline | 6.7 ± 1.2 | 7.6 ± 2.4 | < 0.001 |
Number of concomitant medications at baseline | 1.8 ± 1.7 | 3.1 ± 2.5 | < 0.001 |
Mean dose of ChEI during follow-up period, mg | |||
Donepezil (n = 516)a | 7.4 ± 1.9 (40%) | 6.8 ± 1.7 (52%) | 0.020 |
Rivastigmine (n = 211)a | 6.6 ± 2.3 (26.5%) | 6.0 ± 2.1 (20%) | 0.100 |
Galantamine (n = 290)a | 15.8 ± 3.6 (33.5%) | 15.1 ± 3.8 (28%) | 0.184 |